Castle Biosciences, Inc. (CSTL)
NASDAQ: CSTL · Real-Time Price · USD
27.53
+0.44 (1.62%)
Dec 20, 2024, 4:00 PM EST - Market closed
Castle Biosciences Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for Castle Biosciences stock have an average target of 39.67, with a low estimate of 36 and a high estimate of 44. The average target predicts an increase of 44.10% from the current stock price of 27.53.
Analyst Consensus: Strong Buy
* Price targets were last updated on Nov 6, 2024.
Analyst Ratings
The average analyst rating for CSTL stock from 6 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 1 | 1 | 3 | 3 | 2 |
| Buy | 4 | 4 | 4 | 3 | 4 | 4 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 5 | 5 | 6 | 7 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Scotiabank | Scotiabank | Buy Maintains $37 → $44 | Buy | Maintains | $37 → $44 | +59.83% | Nov 6, 2024 |
| Lake Street | Lake Street | Strong Buy Maintains $34 → $40 | Strong Buy | Maintains | $34 → $40 | +45.30% | Nov 5, 2024 |
| Keybanc | Keybanc | Buy Maintains $28 → $36 | Buy | Maintains | $28 → $36 | +30.77% | Nov 5, 2024 |
| Baird | Baird | Buy Maintains $37 → $39 | Buy | Maintains | $37 → $39 | +41.66% | Nov 5, 2024 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $35 → $42 | Strong Buy | Maintains | $35 → $42 | +52.56% | Oct 29, 2024 |
Financial Forecast
Revenue This Year
332.67M
from 219.79M
Increased by 51.36%
Revenue Next Year
270.95M
from 332.67M
Decreased by -18.55%
EPS This Year
0.36
from -2.14
EPS Next Year
-2.08
from 0.36
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 346.7M | 307.8M | 348.3M | |||
| Avg | 332.7M | 271.0M | 308.9M | |||
| Low | 314.7M | 240.1M | 274.4M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 57.7% | -7.5% | 28.6% | |||
| Avg | 51.4% | -18.6% | 14.0% | |||
| Low | 43.2% | -27.8% | 1.3% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 0.59 | -1.16 | -0.42 | |||
| Avg | 0.36 | -2.08 | -1.37 | |||
| Low | 0.24 | -2.88 | -1.99 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.